Isabella Bon

P15 Changes in bone mineral density and bone turnover markers in antiretroviral therapy-naïve people with HIV starting bictegravir/emtricitabine/tenofovir alafenamide or doravirine/lamivudine/tenofovir disoproxil fumarate

Leonardo Calza, Maria La Giglia, Cristina Rigamonti, Alberto Zuppiroli et autres

Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia

Leonardo Calza, Vincenzo Colangeli, Maddalena Giglia, Isabella Bon et autres

BACKGROUND: Dual regimen dolutegravir/lamivudine (DOL/3TC) showed potent efficacy and favorable safety in both antiretroviral therapy-naive and therapy-experienced patients, but data from real life about naive people with high-level viremia are still lacking. METHODS: We performed a retrospective cohort study of people living …

it (code pays fourni par la source)

Validation of a Duplex real-time PCR assay for the microbiological diagnosis of Rickettsia spp. infection in the metropolitan area of Bologna

E. C. Borgatti, Gianni Virgili, Greta Roncarati, Isabella Bon et autres

Not available.

it (code pays fourni par la source)

Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy

Daniele Armenia, Luca Carioti, Valeria Micheli, Isabella Bon et autres

BACKGROUND: Next-generation sequencing (NGS) is gradually replacing Sanger sequencing for HIV genotypic drug resistance testing (GRT). This work evaluated the concordance among different NGS-GRT interpretation tools in a real-life setting. METHODS: Routine NGS-GRT data were generated from viral RNA at 11 Italian …

it (code pays fourni par la source)

Improvement in insulin sensitivity after switching from an integrase inhibitor‐based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain

Leonardo Calza, Maddalena Giglia, Vincenzo Colangeli, Isabella Bon et autres

OBJECTIVES: We performed an observational, retrospective, cohort study to assess changes in insulin sensitivity after a switch from dolutegravir/lamivudine (DOL/3TC) or bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) to doravirine/tenofovir disoproxil fumarate/3TC (DOR/TDF/3TC) in virologically suppressed people living with HIV with recent significant weight gain. METHODS: …

it (code pays fourni par la source)

Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience

Leonardo Calza, Vincenzo Colangeli, Giulia Pensalfine, Lucia Appolloni et autres

Background Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) showing high efficacy and tolerability in both naïve and experienced people living with HIV (PLWHIV) in randomized trials, but scarce data are available to date from the real-life experience. Methods We performed an …

it (code pays fourni par la source)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years

Leonardo Calza, Vincenzo Colangeli, Giorgio Legnani, Silvia Cretella et autres

Clinical trials of dual regimen dolutegravir/lamivudine (DOL/3TC) demonstrated potent efficacy and favorable safety in both antiretroviral therapy-naïve and -experienced patients, but data on older people are lacking. We aimed to evaluate virological efficacy and safety of DOL/3TC in suppressed older patients over …

it (code pays fourni par la source)

Changes in Serum Inflammatory Markers in Antiretroviral Therapy–Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir

Leonardo Calza, Isabella Bon, Giulia Pensalfine, Salvatore Giovanni Vitale et autres

Our study seems to confirm that dual therapy dolutegravir/ lamivudine is not associated with an increased risk of worsening inflammatory state in antiretroviral therapy–naive persons in comparison with standard triple regimens.

External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy

Ilaria Vicenti, Filippo Dragoni, Alessia Giannini, Anna Casabianca et autres

Abstract Total cell-associated HIV-1 DNA is a surrogate marker of the HIV-1 reservoir, however, certified systems for its quantification are not available. The Italian HIV DNA Network was launched to validate HIV-1 DNA quantification methods in use at University and Hospital labs. …

it (code pays fourni par la source)

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Teresa Miani et autres

In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine/bictegravir.

it (code pays fourni par la source)

Restriction Factors expression decreases in HIV-1 patients after cART.

Vanessa D’Urbano, Alessia Bertoldi, Maria Carla Re, Elisa De Crignis et autres

Activation of interferon (IFN) mediated responses and the consequent expression of restriction factors (RFs) represent an early line of defense against HIV-1 infection. The levels of viral replication and the antiviral are among the determinants influencing RFs' expression pattern. A deeper understanding …

it, us (code pays fourni par la source)

Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19

Angela Chiereghin, Rocco Maurizio Zagari, Silvia Galli, Alessandra Moroni et autres

Introduction: Few data on the diagnostic performance of serological tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently available. We evaluated sensitivity and specificity of five different widely used commercial serological assays for the detection of SARS-CoV-2–specific IgG, IgM, …

it (code pays fourni par la source)